VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

Phase 3 Active not recruiting 1100 enrolled Viking Therapeutics, Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight

Timeline

Start: 2025-06-23
Primary completion: 2027-07-01
Completion: 2027-08-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VK2735	Peptide	7.5 mg	Subcutaneous
Subject	VK2735	Peptide	12.5 mg	Subcutaneous
Subject	VK2735	Peptide	17.5 mg	Subcutaneous

Indications

No indication recorded.